![]() ![]() ![]() Khosla Ventures and Y Combinator co-led the seed investment that also included Metaplanet, Massachusetts Manufacturing Innovation Initiative, Rsquared, Vituity, Paul Buchheit, Balaji Srinivasan, Bob Lee, and Longevity Tech Fund. The Series A round, which closed recently, was led by Intel Capital with participation from Khosla Ventures, Kortex Ventures, Alumni Ventures, Metaplanet, Shorewind Capital, LongeVC, Overlap Holdings and Duke Capital Partners. SiPhox Health’s work is also being boosted by a $27 million round of funding that includes $10 million in seed and $17 million in new Series A capital. The diagnostic market has made a big shift to at-home, driven by companies like Everlywell and supplemented by startups all over the world, including Oova, Simple HealthKit, Senzo, Healthtracka, TBD Health, Starling Medical and Hormona, which have attracted venture capital attention in recent years. The company is gearing up to do a case study on this with thousands of people. The platform will offer proteins and hormone tests from a finger-prick blood sample, with results in five minutes or less. Food and Drug Administration clearance in the next year. ![]() SiPhox Health is working toward getting the SiPhox Home product through U.S. The price of its future offering, which will include the SiPhox Home product, will be subscription-based at less than $100 per month, the company said. It is working on the development of an at-home device, but it is not on the market yet, Dubrovsky said in an interview. Sold on a subscription basis, kits are $95 with a monthly membership of $16 that includes perks like access to continuous glucose monitors and personalized biohacking tools.īig Tech corporate venture capital □ generative AI startupsĬurrently, it is running the tests using mail-in samples and conventional technology. The company offers a test kit and tests for 17 biomarkers, essentially your basic panel, in the areas of inflammation, cardiovascular health, metabolic fitness and hormone balance. “Silicon photonics technology leaves the instrument completely untouched, so we inherit all the functionality, multiplexing capability, sensitivity and so on, and bring that to the consumer.”Īnd, rather than rely on one blood test per year to assess someone’s health, SiPhox Health enables patients and their doctors to get lots of data points to better help make real-time health decisions. “Our approach is to miniaturize all the components onto silicon chips,” he told TechCrunch. SiPhox Health, instead, started with the more expensive side - the lab instrument. Its first product was a $1 COVID-19 test on a disposable cartridge.ĬEO Vermeulen explained that other at-home blood-testing technologies focused on the paper strip and other collection methods that are the less expensive components, rather than on the testing device. At the time, the Burlington, Massachusetts–based company was developing a circuit board for optical chips with a goal of replacing refrigerator-sized diagnostic machines with a tiny chip. MIT scientists Diedrik Vermeulen and Michael Dubrovsky started the company in 2020 and were part of the Y Combinator summer cohort that year. This is the semiconductor technology that transformed internet connectivity. SiPhox Health wants to change that through more advanced blood testing using silicon photonic chip technology to put a lab-grade health testing device in every home. Six out of 10 Americans are living with a chronic disease, but access to convenient and low-cost health testing isn’t always available for patients, and bottlenecks still exist with current testing approaches. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |